Skip to content

Safety and Efficacy of Small Frequent Paracentesis Using an Indwelling CAtheter Compared With Repeated Large Volume Paracentesis in Cirrhotic Patients With REfractory Ascites

Safety and Efficacy of Small Frequent Paracentesis Using an Indwelling CAtheter Compared With Repeated Large Volume Paracentesis in Cirrhotic Patients With REfractory Ascites- A Randomized Controlled Trial (I-CARE)

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04406298
Enrollment
200
Registered
2020-05-28
Start date
2020-07-04
Completion date
2021-05-20
Last updated
2020-07-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver Cirrhosis

Brief summary

The aim of the study is to assess the efficacy of intermittent small quantity (upto 3L per day) paracentesis through an indwelling catheter for up to 5 days in comparison with large volume paracentesis on decreasing the need for repeated paracentesis by 50 % over next 3 months. The project will be conducted at ILBS between April 2020 and March 2021. The concept of the study is to evaluate the efficacy of indwelling catheter in reducing the refilling rates of ascites by 50 % over 3 months in comparison to LVPs and also in reducing the incidence and risk of PPCD. All refractory ascites patients will be included as per inclusion and exclusion criteria, after taking informed consent from the patient or their relatives. The expected outcomes are Primary outcome: Proportion of cirrhotic patients with refractory ascites achieving at least 50 % reduction on need for large volume paracentesis after a short duration (5day) intermittent small quantity (up to 3L/ day) paracentesis through an indwelling catheter in comparison to a single large volume paracentesis in the next 3 months. Secondary outcome: 1\. Proportion of cirrhotic patients with refractory ascites developing P 2 . During a 30 D, 60 D and 90 D follow up, to assess between the groups * Need for repeated paracentesis : Number assessed * AKI : Improvement or worsening of renal functions * Hepatic encephalopathy: Grading as per West Haven Classification * Hyponatremia * Diuretic tolerability : Dose and duration tolerated * Bacterial peritonitis : Ascitic fluid neutrophil count \> 250 cells/cumm * Transplant free survival * Risk of procedure related complications * Changes in MELD or CTP between the groups ( Improvement vs worsening ) * Need for hospitalization between the groups

Interventions

PROCEDUREsmall quantity paracentesis

Intermittent small quantity paracentesis (upto 3L/day) for upto 5 days

Large Volume Paracentesis \> 5litres

Sponsors

Institute of Liver and Biliary Sciences, India
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

* Cirrhotic patients 18-70 yrs with refractory severe ascites with stable renal function (S.creatinine \< 2 mg/dl).

Exclusion criteria

* CTP \>12, MELD\>25 * Prior or current Spontaneous Bacterial Peritonitis (SBP) * Recurrent or current overt hepatic encephalopathy * Serum Creatinine \>2 * HVOTO (Hepatic Venous Outflow Tract Obstruction) * Hepatic or extrahepatic malignancy * Recent UGI bleed * Sepsis * Serum Sodium \< 120

Design outcomes

Primary

MeasureTime frame
Proportion of cirrhotic patients with refractory ascites achieving at least 50 % reduction on need for large volume paracentesis in both groups3 Months

Secondary

MeasureTime frameDescription
Number of participants which requires for repeated paracentesis in both groups90 days
Number of participants with AKI : Improvement or worsening of renal functions in both groups30 days
Number of participants with Hepatic Encephalopathy in both groups30 daysGrading of Hepatic Encephalopathy will be as per West Haven Classification (Score 1 to 4) in both groups
Number of participants with Hyponatremia in both groups30 days
Diuretic tolerability : Dose tolerated in both groups30 days
Diuretic tolerability : Duration tolerated in both groups30 days
Number of participants which requires repeated paracentesis in both groups30 days
Transplant free survival in both groups30 days
Number of participants develop adverse events associated with procedure in both groups30 days
Change in Model for End Stage Liver Disease Score in both groups30 daysMELD Score ranges from 6 to 40
Change in CTP (Child-Turcotte-Pugh) Score in both groups30 daysChild class A: \< 7 points. Child class B: 7-9 points. Child class C: ≥10 points
Number of patients required hospitalization between the groups30 days
Bacterial peritonitis : Ascitic fluid neutrophil count > 250 cells/cumm in both groups30 days

Countries

India

Contacts

Primary ContactDr Manasa Alla, MD
manasa1512@gmail.com01146300000

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026